Pancreatic Cancer Research

ResearcherMassachusetts Institute of TechnologyActive in the last 2 years

Yingjie Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2543-9808; OpenAlex author ID A5103059471. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 3

  1. Platinum Prodrug Nanoparticles with COX-2 Inhibition Amplify Pyroptosis for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer. Last author DOI 10.1002/adma.202310456↗
  2. Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria. Co-author DOI 10.1002/adma.202206765↗
  3. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Co-author DOI 10.1021/acs.nanolett.7b04043↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bingzheng Yu · 1 shared paper, 2024 · strength 0.23
  2. Xing Wang · 1 shared paper, 2022 · strength 0.15
  3. Xiaoxu Kang · 1 shared paper, 2022 · strength 0.15
  4. Paiman Peter Ghoroghchian · 1 shared paper, 2018 · strength 0.08
  5. Xing Huang · 1 shared paper, 2018 · strength 0.08
  6. Zhimin Tao · 1 shared paper, 2018 · strength 0.08
  7. Mandar Deepak Muzumdar · 1 shared paper, 2018 · strength 0.08
  8. Tyler Jacks · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.